[Blepharitis related to Cetuximab treatment in an advanced colorectal cancer patient]. / Blefaritis asociada al tratamiento con Cetuximab en adenocarcinoma colorrectal avanzado.
Arch Soc Esp Oftalmol
; 83(11): 665-8, 2008 Nov.
Article
en Es
| MEDLINE
| ID: mdl-19006019
CASE REPORT: A 52-year-old woman with advanced colorectal cancer was referred to us for treatment of Cetuximab-related ocular side-effects. DISCUSSION: Cetuximab is a monoclonal antibody that specifically blocks epidermal growth factor receptor activity. It has recently been approved to treat some tumors such as metastatic colorectal cancer and some ORL cancers. Tolerance to it seems to be better than that to the classic chemotherapeutic agents. However it has several side-effects. Cetuximab-related eyelid toxicity has been recently described, though the pathogenesis has not yet been clearly established.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Blefaritis
/
Neoplasias Colorrectales
/
Anticuerpos Monoclonales
/
Antineoplásicos
Límite:
Female
/
Humans
/
Middle aged
Idioma:
Es
Revista:
Arch Soc Esp Oftalmol
Año:
2008
Tipo del documento:
Article
Pais de publicación:
España